CryoCath Technologies
This article was originally published in The Gray Sheet
Executive Summary
Canadian initial public offering raises approximately $25.9 mil. (based on current exchange rates) to support clinical trials and commercialization of the Freezor focal ablation catheter system for tachyarrhythmia treatment, including atrial fibrillation. The funds also will go toward trials of the firm's CryoStent for post-angioplasty restenosis and CryoVasc system for cardiac ischemia. The offering included 5 mil. shares at about $5.17 each. The stock is listed on the Toronto exchange under the symbol "CYT." The IPO syndicate was led by Yorkton Securities and included CIBC World Markets, National Bank Financial and Loewen, Ondaatje, McCutcheon Limited
You may also be interested in...
California Court’s Inaction On TiO2 Prop 65 First Amendment Case Breeds New Lawsuits
The Personal Care Products Council seeks to stem the rising tide of titanium dioxide Proposition 65 lawsuits, requesting that a California court prohibit the state’s Attorney General and private enforcers from filing and/or prosecuting new suits against cosmetics companies failing to warn about potential TiO2 exposure.
Kenvue Breaks Ground On New Headquarters, Appoints Chief Corporate Affairs Officer
Firm hosts groundbreaking for 290,000 square-foot global headquarters it’s having built in Summit, NJ, starting with 100,000 square-foot science and innovation and expected to open in 2025. It announced adding Russell Dyer as chief corporate affairs officer starting 13 March.
Xaira Launches With $1bn-Plus And End-To-End AI Strategy
ARCH and Foresite incubated the company and recruited Genentech R&D veteran Marc Tessier-Lavigne to keep data generation, machine learning research and drug development under one roof.